gdc-0973 has been researched along with Histiocytosis* in 2 studies
1 trial(s) available for gdc-0973 and Histiocytosis
| Article | Year |
|---|---|
Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Histiocytic neoplasms are a heterogeneous group of clonal haematopoietic disorders that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway Topics: Azetidines; Histiocytic Disorders, Malignant; Histiocytosis; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Mutation; Piperidines; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf | 2019 |
1 other study(ies) available for gdc-0973 and Histiocytosis
| Article | Year |
|---|---|
Progressive nodular histiocytosis in a 9-year-old boy treated with cobimetinib.
Progressive nodular histiocytosis is a rare variant of non-Langerhans cell histiocytosis that affects the skin and mucous membranes and displays a progressive clinical course and poor response to treatment. We describe a case of severe progressive nodular histiocytosis harboring a KRAS p.G12S mutation in a 9-year-old boy, refractory to chemotherapy, who was successfully treated with the MEK inhibitor cobimetinib. This is the first report of the use of MEK inhibition for this histiocytosis subtype in a pediatric patient. Topics: Azetidines; Child; Histiocytosis; Histiocytosis, Langerhans-Cell; Humans; Male; Piperidines; Skin Diseases | 2022 |